Yan Wu on Muck Rack

Yan Wu

Taunton
As seen in: Medium, British Journal of Cancer, Color Research & Application, Nature, The Washington Post, Washington Post Opinions, Wiley Online Library, British Pharmacological Society, PLOS, PLOS ONE and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yan

Contact Yan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Lateral septum GABAergic neurons mediate the effects of dexmedetomidine on allodynia and sleep in a male mouse model of neuropathic pain

|
By Yingying Su, Jie Deng, Meiying Chen, Kaibin Wu, Peiwen Tang, Chen Wang, Deyi Kong, Ting Xu, Feixue Liang, Wenjun Xin, Yan Wu, Xia Feng, Haiting Fan, Zhengkai Liang
| Nature Verified
Abstract Chronic pain and sleep disorders frequently co-occur and exacerbate each other, yet the neural mechanisms underlying this comorbidity remain poorly understood. Here, we found that hyperactivity of GABAergic neurons in the dorsal division of the lateral septum (LSGABA) drives both pain-like behavior and sleep disruption induced by spared nerve injury (SNI) in male mice.
Open in Who Shared Issue with article?

Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial

|
By Li Wang, Chuangzhou Rao, Qi Wang, Li N Liu, Jing Zhao, Yan Wu, Jianing Chen, Jialin Qian, Haijiao Lu, Haoran Tang, Hang Dong, Tianqing Chu, Chunxia Su, Kuofang Huang, Shifei Pan, Liangqin Nie, Shi-Dong Jia, Yichao Zang
| Nature Verified
Abstract Although immunotherapy is approved for patients with high PD-L1 expression, optimal therapeutic strategies for PD-L1-negative populations remain undefined. This study (ChiCTR2300071681) assessed the efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy in patients with PD-L1-negative advanced non-small-cell lung cancer (NSCLC).
Open in Who Shared Issue with article?

Photocatalytic Hydrodisulfuration of Alkenes Using N -Perthiophthalimides as Perthiyl Radical Sources Click to copy article link Article link copied!

|
By Yan Wu, Yuqi Gong, Hao Qin
| dx.doi.org
Open in Who Shared Issue with article?
See all 430 licensed articles (453 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified